产品
编 号：F760749
分子式：C19H20N4O
分子量：320.39
分子式：C19H20N4O
分子量：320.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 855291-54-2
产品详情
生物活性：
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
体内研究：
ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly, 100%), and good CNS penetration in rodents with a brain/plasma ratio of 1.ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB. ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S9-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice.ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice.Animal Model:Rats (male Sprague-Dawley; 350-380 g b.wt.).
Dosage:1, 3 μmol/kg.
Administration:I.P. daily for 3 consecutive days.
Result:Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration.Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior.
Animal Model:Female TAPP (and wild-type littermates) mice.
Dosage:1 mg/kg.
Administration:Continuous subcutaneous infusion for 2 weeks.
Result:Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice.
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
体内研究：
ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly, 100%), and good CNS penetration in rodents with a brain/plasma ratio of 1.ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB. ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S9-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice.ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice.Animal Model:Rats (male Sprague-Dawley; 350-380 g b.wt.).
Dosage:1, 3 μmol/kg.
Administration:I.P. daily for 3 consecutive days.
Result:Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration.Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior.
Animal Model:Female TAPP (and wild-type littermates) mice.
Dosage:1 mg/kg.
Administration:Continuous subcutaneous infusion for 2 weeks.
Result:Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备